BioVector? 支原體表達載體

BioVector? Mycoplasma Expression Vector

第一部分：中文說明

一、 產(chǎn)品基本信息與遺傳學背景

• 載體類型：原核表達載體（支原體屬特異性穩(wěn)定表達質(zhì)粒系統(tǒng)）

• 物種適用性：主要適用于肺炎支原體 (Mycoplasma pneumoniae)、生殖支原體 (Mycoplasma genitalium)、山羊支原體 (Mycoplasma capricolum) 及絲狀支原體等。

• 遺傳密碼特異性（密碼子優(yōu)化核心）：

  • 關(guān)鍵遺傳學屏障：支原體屬（Mycoplasma）具有獨特的遺傳密碼，將 UGA 終止密碼子重新定義為編碼色氨酸（Tryptophan, Trp）。

  • 設(shè)計要求：若在常規(guī)大腸桿菌表達載體中表達外源基因，遇到 UGA 會提前終止。本系統(tǒng)采用針對支原體特異性優(yōu)化的密碼子體系。若目標蛋白需在支原體內(nèi)高效表達，其序列中的色氨酸位點必須對應(yīng) UGA；若在常規(guī)宿主中克隆，則需注意此密碼子偏好性的切換。

• 復(fù)制子與維持元件：

  • 攜帶源自支原體天然質(zhì)粒（如 pGyl 類似物）的支原體特異性復(fù)制起始位點（oriC），確保其在支原體細胞分裂時能穩(wěn)定分配。

  • 包含大腸桿菌復(fù)制子（如 pUC ori），用于在 E. coli 菌株中進行高拷貝克隆與質(zhì)粒擴增。

• 篩選標記：通常配置四環(huán)素抗性基因（tetM）或紅霉素抗性基因（ermB），該類標記由支原體強啟動子驅(qū)動，用于在轉(zhuǎn)化后的支原體中進行穩(wěn)定抗性篩選。

二、 分子結(jié)構(gòu)特征與克隆環(huán)境

• 啟動子系統(tǒng)：由支原體高表達延伸因子啟動子（如 P_tuf）或核糖體蛋白亞基啟動子（如 P_rpsD）驅(qū)動，確保外源基因在缺乏復(fù)雜轉(zhuǎn)錄調(diào)控機制的支原體胞內(nèi)實現(xiàn)持續(xù)高水平的組成型表達。

• 多克隆位點（MCS）：配置常用的獨特性限制性內(nèi)切酶切點（如 BamHI, EcoRI, XhoI, HindIII 等），方便外源片段的精準插入。

• 標簽選擇（Tags）：通?？蛇x融合 C-端或 N-端的 6×His-tag、Flag-tag，便于后續(xù)利用免疫印跡（Western Blot）或親和層析對支原體表達產(chǎn)物進行鑒定與純化。

• 生物安全級別：1級或2級（BSL-1 / BSL-2）。載體本身為安全的原核質(zhì)粒，但當其轉(zhuǎn)化入致病性支原體（如肺炎支原體）時，后續(xù)的細胞培養(yǎng)與操作必須嚴格在二級生物安全柜中進行。

三、 轉(zhuǎn)化與篩選標準操作步驟

1. 大腸桿菌擴增與質(zhì)粒制備：

   • 將載體質(zhì)粒轉(zhuǎn)化至常規(guī)大腸桿菌受體菌（如 DH5α、Top10），接種于含相應(yīng)抗生素（如氨芐青霉素或紅霉素）的 LB 培養(yǎng)基中。

   • 37°C 振蕩培養(yǎng)過夜，使用無毒素或高純度質(zhì)粒提取試劑盒提取質(zhì)粒，測序驗證 MCS 區(qū)段插入方向及讀碼框的正確性。

2. 支原體電轉(zhuǎn)化（Electroporation）：

   • 收集處于對數(shù)生長期的支原體液體培養(yǎng)物，利用冰冷的高滲清洗液（如 8-272 mM 的蔗糖溶液或電轉(zhuǎn)緩沖液）進行多次洗滌，制備高密度的支原體電轉(zhuǎn)感受態(tài)細胞。

   • 取 50–100 μL 感受態(tài)細胞懸液置于預(yù)冷的電轉(zhuǎn)杯中，加入 1–5 μg 的高純度純化質(zhì)粒，混勻后冰孵。

   • 根據(jù)具體的支原體種屬設(shè)置電擊參數(shù)（通常為高電壓、短時間沖入，如：電壓 1.25–2.5 kV，電容 25 μF，電阻 100–400 Ω）。

   • 電擊后立即加入預(yù)熱的支原體完全肉湯培養(yǎng)基（如 SP4 或 Hayflick 培養(yǎng)基），在無抗生素條件下于 37°C 復(fù)蘇培養(yǎng) 2–4 小時，以恢復(fù)膜完整性并表達抗性標記。

3. 抗性平板篩選：

   • 將復(fù)蘇后的菌液涂布于含有對應(yīng)篩選抗生素（如 2–10 μg/mL 四環(huán)素或紅霉素）的支原體固體瓊脂平板上。

   • 置于 37°C 恒溫（或 5% $CO_2$ 微需氧環(huán)境）下培養(yǎng) 5–14 天，直至平板上長出特征性的“油煎蛋”狀支原體轉(zhuǎn)化子菌落。

四、 核心科研應(yīng)用方向

1. 支原體基因功能驗證與補救實驗（Complementation）：用于將野生型基因?qū)牖蚯贸蛲蛔兊闹гw弱毒株中，恢復(fù)其表型，從而確證特定基因（如粘附素、毒力因子）的功能。

2. 支原體表面抗原與疫苗靶點表達：在支原體本土系統(tǒng)中表達并展示高度構(gòu)象依賴性的表面膜蛋白，用于研究宿主-病原體相互作用，或開發(fā)針對支原體感染的新型亞單位疫苗。

3. 病原體宿主互作分子機制研究：通過融合表達熒光蛋白（如 GFP、mCherry），在細胞水平實時動態(tài)示蹤支原體對宿主上皮細胞的粘附、入侵及胞內(nèi)定殖過程。

PART 2: ENGLISH SECTION

I. General Information and Genetic Background

• Vector Type: Prokaryote Expression Vector (Mycoplasma genus-specific stable expression plasmid system).

• Species Compatibility: Tailored for Mycoplasma pneumoniae, Mycoplasma genitalium, Mycoplasma capricolum, Mycoplasma mycoides, and related species.

• Genetic Code Specificity (Codon Optimization Core):

  • Critical Translational Barrier: The genus Mycoplasma utilizes a non-standard genetic code where the UGA codon is reassigned from a stop codon to code for Tryptophan (Trp).

  • Design Obligation: Standard E. coli vectors will cause premature translation termination at UGA sites. This system utilizes a custom framework tailored for mycoplasmal translation. When cloning target genes, codon selection must match this reassignment for robust product yielding inside the mycoplasma host.

• Replicon & Maintenance Elements:

  • Equipped with a mycoplasma-specific chromosomal origin of replication (oriC) derived from endogenous plasmids (e.g., pGyl analogues), guaranteeing stable partitioning during binary fission.

  • Contains a standard E. coli replicon (such as pUC ori) for high-copy cloning and easy plasmid preparation inside standard enterobacterial strains.

• Selection Marker: Commonly driven by a strong constitutively active mycoplasmal promoter upstream of either a tetracycline resistance gene (tetM) or an erythromycin resistance gene (ermB) for selective screening post-transformation.

II. Molecular Architecture and Cloning Settings

• Promoter System: Governed by high-efficiency house-keeping mycoplasmal promoters, such as the elongation factor tu promoter (P_tuf) or the ribosomal protein subunit D promoter (P_rpsD), ensuring strong, continuous, constitutive transcription without requiring chemical inducers.

• Multiple Cloning Site (MCS): Furnished with unique restriction sites (e.g., BamHI, EcoRI, XhoI, HindIII) to simplify directional insertion of target genes.

• Epitope Tagging Options: Available with terminal 6×His-tag or Flag-tag options at either the N- or C-terminus, streamlining Western Blot profiling and affinity chromatography capture processing.

• Biosafety Level: BSL-1 (for the naked plasmid) / BSL-2 (post-transformation). The vector itself is non-hazardous. However, once introduced into pathogenic strains like M. pneumoniae, all downstream culture lines must be contained within Class II Biosafety Cabinets.

III. Transformation and Selection Protocols

1. Plasmid Amplification in E. coli:

   • Transform the expression construct into standard E. coli competent cells (e.g., DH5α, Top10) and plate on LB agar supplemented with the appropriate selection agent.

   • Isolate the plasmid using an endotoxin-free or high-purity miniprep kit and confirm the integrity of the MCS insertion profile via Sanger sequencing.

2. Mycoplasma Electroporation:

   • Harvest mycoplasma liquid cultures during the late exponential growth phase. Wash cells multiple times with an ice-cold, high-osmolarity wash buffer (e.g., 8-272 mM sucrose matrix) to yield dense electrocompetent mycoplasma cells.

   • Aliquot 50–100 μL of competent cells into a pre-chilled electroporation cuvette, mix with 1–5 μg of pure plasmid DNA, and incubate briefly on ice.

   • Apply an electrical pulse customized for small, wall-less prokaryotes (typical parameters: voltage 1.25–2.5 kV, capacitance 25 μF, resistance 100–400 Ω).

   • Immediately rescue the shocked cells by adding pre-warmed complete mycoplasma broth (e.g., SP4 or Hayflick medium) and incubate non-selectively at 37°C for 2–4 hours to facilitate membrane repair and marker expression.

3. Antibiotic Selection Plating:

   • Spread the recovered pool onto solid mycoplasma agar plates containing appropriate selective screening agents (e.g., 2–10 μg/mL tetracycline or erythromycin).

   • Incubate at 37°C (or under a 5% $CO_2$ microaerophilic atmosphere) for 5–14 days until characteristic "fried-egg" morphology colonies emerge.

IV. Strategic Research Applications

1. Gene Function Validation & Genetic Complementation: Used to re-introduce wild-type genes back into knockout mutants or attenuated mycoplasma strains to restore phenotype markers, confirming the exact function of suspected virulence factors or adhesins.

2. Surface Antigen Presentation & Vaccine Development: Enables native conformation-dependent expression of surface-exposed membrane proteins, which is critical for evaluating host-pathogen dynamics or screening antigen targets for subunit vaccine development.

3. Host-Pathogen Interaction Mapping: Facilitates real-time tracking, attachment tracing, and intracellular colonization profiling against host epithelial cells via translational fusion with fluorescent reporters like GFP or mCherry.

BioVector NTCC質(zhì)粒載體菌株細胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號:1843439339

網(wǎng)址

http://www.nedfriskphoto.com